(Q37896347)

25 August 2017

1 reference

title

Targeting of Toll-like receptors: a decade of progress in combating infectious diseases (English)

1 reference

25 August 2017

0 references

3

1 reference

25 August 2017

2

Mihai G Netea

1 reference

25 August 2017

Mona Hedayat

1

1 reference

25 August 2017

28 June 2011

1 reference

25 August 2017

11

1 reference

Lancet Infectious Diseases

inferred from page(s)

published in

1 reference

25 August 2017

11

1 reference

25 August 2017

702-712

1 reference

25 August 2017

9

1 reference

The roles of TLRs, RLRs and NLRs in pathogen recognition

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptor signalling

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Crystal structure of human toll-like receptor 3 (TLR3) ectodomain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptors and innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptors: linking innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptors and T-helper-1/T-helper-2 responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptor 2 controls expansion and function of regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Vaccine adjuvants: scientific challenges and strategic initiatives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Aluminium compounds for use in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

New hepatitis B vaccine formulated with an improved adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative tr

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Structure-activity relationship of synthetic toll-like receptor 4 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

TLR4 agonists as immunomodulatory agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

TLR3: interferon induction by double-stranded RNA including poly(I:C).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Antiviral actions of interferons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Imiquimod for the treatment of genital warts: a quantitative systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

American Gastroenterological Association technical review on the management of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptors, cytokines and HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Mismatched double-stranded RNA, ampligen (poly(I) : poly(C12U)), demonstrates antiviral and immunostimulatory activities in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Structures of the toll-like receptor family and its ligand complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

New insight in LPS antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Recombinant soluble forms of extracellular TLR4 domain and MD-2 inhibit lipopolysaccharide binding on cell surface and dampen lipopolysaccharide-induced pulmonary inflammation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Cell-penetrating peptides for drug delivery across membrane barriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Differential involvement of BB loops of toll-IL-1 resistance (TIR) domain-containing adapter proteins in TLR4- versus TLR2-mediated signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Inhibition of endotoxin response by synthetic TLR4 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Structures of TLR-ligand complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970099-8

7 January 2021

10.1016/S1473-3099(11)70099-8

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21719349